Experimental cancer drug injected directly into tumors shows early promise
NCT ID NCT03444714
Summary
This early-stage study tested a new drug called RiMO-301, which is injected directly into a tumor and combined with a standard radiation treatment. The main goal was to find the highest safe dose for patients with advanced cancers that are accessible for injection. Researchers also looked for early signs that the treatment could shrink tumors or relieve symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.